Search

The MSUD Family Support Group has provided funds to Buck Institute for its preliminary studies investigating metformin , a drug commonly used to treat diabetes, and the impact it may have on the metabolism of branchedchain amino acids (BCAAs) including leucine. They also plan to investigate the use of Triacetoacetin (TAA), a substance which provides molecules which are generated during normal metabolism and which are deficient in individuals with MSUD.

BCAAs play a critical role in the development of muscle tissue. Leucine is a key trigger for muscle protein synthesis and is also used as a fuel source by the muscle, particularly during high intensity exercise. Abnormalities have been observed in the muscle fibers of mice with intermediate MSUD (iMSUD), and have also been observed in critically ill children with classic MSUD.

As an initial step, the researchers have developed the tools they will use to demonstrate an effect of treatment on muscle fiber size and muscle strength. They have been able to observe that iMSUD mice have fewer Type 1 “slow twitch” muscle fibers which are used for endurance types of activity. In contrast, they found increased levels of Type 2 “fast twitch” muscle fibers which rely less on oxygen for their fuel and are used for quick bursts of activity.

But on the whole, the ability of the iMSUD mice to utilize glucose was diminished, suggesting an overall physiological defect in MSUD. They also found that the muscles of iMSUD mice were weaker than those of mice without MSUD. After treatment with metformin, iMSUD mice had lower levels of the keto acid which accumulates when leucine levels are high, but had similar levels of leucine. Very encouragingly, treatment with metformin reversed the loss of Type 1 fibers associated with the iMSUD mice. And in conjunction, metformin also restored muscle strength and glucose physiology of these mice. This suggests a promising therapeutic outcome for metformin in the future. The iMSUD mice are short lived with a survival of about 2-3 weeks. The team is now looking at the effect of metformin injections on the lifespan of iMSUD mice. Finally, as the skeletal muscle of iMSUD mice have insufficient biochemicals used in aerobic metabolism, the team will also test ways of supplementing these biochemicals by treatment with TAA as a precursor drug.

Galen Carrington Classic MSUD age 27

Galen Carrington is a 27 year old Indiana resident who has classic MSUD. He underwent liver transplantation 5 years ago at Children’s Hospital

Read More

From The Editor

Hello to my MSUD family! The power of this family hit home this summer, when Hannah (Classic MSUD age 23 years) and I visited Israel.

Read More

From The Chairman’s Desk

On July the 21st the MSUD Board of Directors traveled to Bethesda, Maryland for our annual Board meeting. We stayed at the Hyatt Regency in Bethesda.

Read More

MSUD Advocacy Update

Healthcare and issues facing the rare disease community have been at the forefront of national conversations over the past 6 months.

Read More

Metformin As A Possible Therapeutic Agent In The Treatment Of MSUD

The MSUD Family Support Group has provided funds to Buck Institute for its preliminary studies investigating metformin

Read More

Sweet Odyssey

Artur Santos was born on January 18, 2002, the second son of Soraya and Idario Santos. They never imagined how their lives were about change as the second baby arrived.

Read More

Transform

A Child's Life

Subscribe to our mailing list

Signup To Our Newsletter Signup with your email address to receive news and updates